Coin Press - US orders all Juul vaping products off the market

The decision clears the way for rival brands to increase their share of the market, which Juul once dominated.

"Today's action is further progress on the FDA's commitment to ensuring that all e-cigarette and electronic nicotine delivery system products currently being marketed to consumers meet our public health standards," said FDA Commissioner Robert Califf in a statement.

Products affected include the Juul device and its pods, which currently come in the flavors Virginia tobacco and in menthol, at nicotine concentrations of five and three percent.

After completing a two-year review of the company's marketing application, the FDA found the data presented "lacked sufficient evidence regarding the toxicological profile of the products," it said.

"In particular, some of the company's study findings raised concerns due to insufficient and conflicting data – including regarding genotoxicity and potentially harmful chemicals leaching from the company's proprietary e-liquid pods," it added.

Juul was blamed for a surge in youth vaping over its marketing of fruit and candy flavored e-cigarettes, which it stopped selling in 2019.

In January 2020, the FDA said sale of e-cigarettes in flavors other than tobacco or menthol would be illegal unless specifically authorized by the government.

The agency has approved some e-cigarette products from other makers such as Reynolds American, the current market leader, NJOY and Logic Technology Development.

Juul has argued that vaping products can provide a solution to the harmful health impacts from conventional cigarettes.

Juul's products "exist only to transition adult smokers away from combustible cigarettes," Chief Executive KC Crosthwaite said on the company's website, adding that the company is "working hard" to rebuild its reputation following an "erosion of trust over the past few years."

On Tuesday, President Joe Biden's administration announced it would develop a new policy requiring cigarette producers to reduce nicotine to non-addictive levels.

The initiative requires the FDA to develop and then publish a rule, which will likely be contested by industry.

Y.Jeong--CPN